HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With OTC Lidocaine, Salonpas Takes Path Of Less Resistance To Market

This article was originally published in The Pink Sheet

Executive Summary

Hisamitsu America looked to the OTC lidocaine market after deciding it would have to wait too long for an ANDA approval for an Rx generic. "We really saw the opportunity in the OTC space with a 4% OTC patch," says President and CEO John Incledon.

You may also be interested in...

Salonpas Samples Its History To Attach US, Canadian Consumers To Topical Analgesics

"Our eyes are more on Advil, Tylenol. We want to be considered first-line treatment for pain, for pain appropriate for what our products are," says Hisamitsu America CEO John Incledon.

Salonpas Ad Claims Pass FTC Test After Firm Refuses NAD Review

NAD cases do not go to FTC with a guarantee of enforcement, but firms should not ignore NAD requests for substantiation. FTC declined to enforce against Hisamitsu’s claims for Salonpas OTC pain relief patches after the firm declined to provide information for a NAD review prompted by a Pfizer challenge.

Promescent OTC For Premature Ejaculation Builds On Physician Strategy

Sales of Promescent, an OTC external analgesic indicated for premature ejaculation available for 18 months online, jumped in the past year with distribution by urologists and other doctors. “The PE space is wide open. That is nothing short of amazing to me,” says Absorption Pharmaceuticals CEO Jeff Abraham.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts